Arcutis Biotherapeutics (ARQT) Intangibles (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Intangibles of $14.2 million for Q1 2026, down 13.64% year-over-year from $16.5 million in Q1 2025, and down 3.79% quarter-over-quarter from $14.8 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Intangibles (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Intangibles history runs 5 years deep, the most recent figure standing at $14.2 million for Q1 2026.
- In Q1 2026, Intangibles fell 13.64% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.2 million (down 13.64% YoY), while the FY2025 annual figure was $14.8 million, up 56.26% from the prior year.
- Intangibles for Q1 2026 stood at $14.2 million, down from $14.8 million in the prior quarter.
- The five-year high for Intangibles was $16.5 million in Q1 2025, with the low at $6.1 million in Q2 2024.
- The 5-year median for Intangibles is $7.4 million (2022), against an average of $10.0 million.
- The sharpest annual moves came in 2025 and 2026: Intangibles surged 164.0% in 2025, then dropped 13.64% in 2026.
- Arcutis Biotherapeutics' Intangibles stood at $7.2 million in 2022, then declined by 10.43% to $6.4 million in 2023, then jumped by 47.24% to $9.5 million in 2024, then soared by 56.26% to $14.8 million in 2025, then dropped by 3.79% to $14.2 million in 2026.
- Business Quant data shows ARQT's Intangibles at $14.2 million in Q1 2026, $14.8 million in Q4 2025, and $15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 13.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.69 Mn |
| Mar 31, 2026 | 14.25 Mn |
| Dec 31, 2025 | 14.81 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Jun 30, 2025 | 15.94 Mn |
| Mar 31, 2025 | 16.50 Mn |
| Dec 31, 2024 | 9.48 Mn |
| Sep 30, 2024 | 9.79 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 6.44 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | 6.81 Mn |
| Mar 31, 2023 | 7.00 Mn |
| Dec 31, 2022 | 7.19 Mn |
| Sep 30, 2022 | 7.38 Mn |